“Some days I get up and can’t imagine how significantly we’ve occur,” stated Dr. Doblin, 67, who now oversees the Multidisciplinary Association for Psychedelic Research, a multimillion greenback study and advocacy empire that employs 130 neuroscientists, pharmacologists and regulatory specialists working to lay the groundwork for the coming